Infection of the vulva and vagina
Also known as: Vulvovaginitis
Methodology & AI Transparency ⓘ
Infection of the vulva and vagina Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as N76.0, Infection of the vulva and vagina (also termed Vulvovaginitis) falls under Infections & Antivirals management, where antimicrobial stewardship (narrow-spectrum in Infection of the vulva and vagina (N76.0: pathogen-directed duration) or) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Infection of the vulva and vagina uses ICD-10 N76.0 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Workup highlights for Infection of the vulva and vagina (N76.0): antimicrobial stewardship (narrow-spectrum in Infection of the vulva and vagina (N76.0: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for Infection of the vulva and vagina (N76.0): C-Reactive Protein / in Infection of the vulva and vagina (N76.0: Procalcitonin) & Targeted PCR / in Infection of the vulva and vagina (N76.0: Culture & Sensitivity) (Pathogen clearance / negative test (N76.0)).
Ask our AI Specialists anything about Infection of the vulva and vagina
What Is Infection of the vulva and vagina?
Designated in federal medical registries as N76.0, Infection of the vulva and vagina (also termed Vulvovaginitis) falls under Infections & Antivirals management, where antimicrobial stewardship (narrow-spectrum in Infection of the vulva and vagina (N76.0: pathogen-directed duration) or) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Infection of the vulva and vagina (N76.0, Infections & Antivirals) reflects or latent viral in Infection of the vulva and vagina (N76.0: reactivation within sensory). longitudinal control is benchmarked via C-Reactive Protein / in Infection of the vulva and vagina (N76.0: Procalcitonin).
Common Symptoms & Clinical Signs
- • Presentation of Infection of the vulva and vagina (N76.0): regional lymph node in Infection of the vulva and vagina (N76.0: tenderness or acute)
- • Secondary Infection of the vulva and vagina clinical sign: acute fever, chills, in Infection of the vulva and vagina (N76.0: malaise, and myalgias)
- • Symptom flares in Infection of the vulva and vagina correlating with C-Reactive Protein / in Infection of the vulva and vagina (N76.0: Procalcitonin) deviation outside Resolution to baseline (N76.0)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Infection of the vulva and vagina (N76.0: pathogen-directed duration) or) evaluation (N76.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Infection of the vulva and vagina Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N76.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: C-Reactive Protein / in Infection of the vulva and vagina (N76.0: Procalcitonin) | Resolution to baseline (N76.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Infection of the vulva and vagina (N76.0: Culture & Sensitivity) | Pathogen clearance / negative test (N76.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Infection of the vulva and vagina (N76.0: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (N76.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Infection of the vulva and vagina
Treatment selection for Infection of the vulva and vagina depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Infection of the vulva and vagina)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children: What a 3,765-Participant Study Found The variability in VE algorithms indicates challenges in accurately assessing VE against asymptomatic infections. The Journal of infectious diseases • 2025-07-11 • Phase III Randomized Trial | N = 3,765 | 96/100 | PMID 40100744 ↗ |
| New Insights on Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated: What a 2,222-Participant Study Found Sulopenem was noninferior to amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection, but was associated with more frequent mild side effects. NEJM evidence • 2025-07-15 • Phase III Randomized Trial | N = 2,222 | 96/100 | PMID 40552968 ↗ |
| New Insights on Long-term protection from naturally acquired immunity against hepatitis E virus: What a 3,194-Participant Study Found Six were hospitalized, all of whom were baseline seronegative. Nature communications • 2025-12-17 • Phase III Randomized Trial | N = 3,194 | 96/100 | PMID 41407683 ↗ |
| New Insights on Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the: What a 1,046-Participant Study Found Both vonoprazan-based regimens were superior to proton pump inhibitor-based triple therapy in clarithromycin-resistant strains and in the overall study population. Gastroenterology • 2022-09-15 • Phase III Randomized Trial | N = 1,046 | 96/100 | PMID 35679950 ↗ |
Infection of the vulva and vagina Patient Community & “People Like Me” Threads
Filter Infection of the vulva and vagina community threads and patient logs by age, biological sex, dosage, and treatment duration.